Stocks
Bluebird Bio Financial Statements (BLUE) |
||||||||||
| Bluebird Biosmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 18.02.2020 | 23.02.2021 | 04.03.2022 | 29.03.2023 | 13.09.2024 | 14.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 44.7 | 250.7 | 3.66 | 3.60 | 29.5 | 53.1 | |||
| Operating Income, bln rub | -812.1 | -629.5 | -590.9 | -287.1 | -244.3 | -316.7 | ||||
| EBITDA, bln rub | ? | -772.7 | -553.6 | -556.9 | -215.6 | -167.2 | -128.2 | |||
| Net profit, bln rub | ? | -789.6 | -618.7 | -562.6 | -266.6 | -211.9 | -300.5 | |||
| OCF, bln rub | ? | -564.4 | -470.4 | -635.6 | -353.0 | -235.0 | -223.7 | |||
| CAPEX, bln rub | ? | 76.3 | 29.0 | 23.0 | 13.2 | 9.06 | 7.33 | |||
| FCF, bln rub | ? | -640.6 | -499.3 | -658.6 | -366.2 | -244.1 | -231.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 853.8 | 874.9 | 529.9 | 275.7 | 240.2 | 290.8 | ||||
| Cost of production, bln rub | 2.98 | 5.40 | 38.9 | 10.1 | 33.5 | 76.2 | ||||
| R&D, bln rub | 582.4 | 588.0 | 319.9 | 240.8 | 167.7 | 107.2 | ||||
| Interest expenses, bln rub | 34.8 | 0.000 | 0.000 | 6.32 | 16.4 | 16.1 | ||||
| Assets, bln rub | 1 727 | 1 781 | 593.8 | 554.9 | 619.2 | 465.1 | ||||
| Net Assets, bln rub | ? | 1 285 | 1 355 | 374.3 | 196.3 | 194.5 | -5.79 | |||
| Debt, bln rub | 191.0 | 193.0 | 89.6 | 281.4 | 330.3 | 368.4 | ||||
| Cash, bln rub | 1 238 | 1 274 | 396.6 | 181.7 | 221.8 | 70.7 | ||||
| Net debt, bln rub | -1 047 | -1 081 | -307.0 | 99.6 | 108.6 | 297.8 | ||||
| Ordinary share price, rub | 56.8 | 28.0 | 9.99 | 6.92 | 1.38 | 3.07 | ||||
| Number of ordinary shares, mln | 55.2 | 62.2 | 68.9 | 78.6 | 109.8 | 193.9 | ||||
| Market cap, bln rub | 3 137 | 1 742 | 688 | 544 | 152 | 595 | ||||
| EV, bln rub | ? | 2 090 | 661 | 381 | 643 | 260 | 893 | |||
| Book value, bln rub | 1 258 | 1 332 | 369 | 186 | 178 | -21 | ||||
| EPS, rub | ? | -14.3 | -9.95 | -8.16 | -3.39 | -1.93 | -1.55 | |||
| FCF/share, rub | -11.6 | -8.03 | -9.56 | -4.66 | -2.22 | -1.19 | ||||
| BV/share, rub | 22.8 | 21.4 | 5.35 | 2.36 | 1.62 | -0.11 | ||||
| EBITDA margin, % | ? | -1 730% | -220.8% | -15 208% | -5 993% | -566.7% | -241.4% | |||
| Net margin, % | ? | -1 767% | -246.8% | -15 364% | -7 411% | -718.4% | -565.7% | |||
| FCF yield, % | ? | -20.4% | -28.7% | -95.7% | -67.3% | -161.1% | -38.8% | |||
| ROE, % | ? | -61.4% | -45.7% | -150.3% | -135.8% | -108.9% | 5 194% | |||
| ROA, % | ? | -45.7% | -34.7% | -94.8% | -48.0% | -34.2% | -64.6% | |||
| P/E | ? | -3.97 | -2.82 | -1.22 | -2.04 | -0.72 | -1.98 | |||
| P/FCF | -4.90 | -3.49 | -1.05 | -1.49 | -0.62 | -2.58 | ||||
| P/S | ? | 70.2 | 6.95 | 188.0 | 151.2 | 5.14 | 11.2 | |||
| P/BV | ? | 2.49 | 1.31 | 1.87 | 2.93 | 0.85 | -28.1 | |||
| EV/EBITDA | ? | -2.70 | -1.19 | -0.68 | -2.99 | -1.56 | -6.96 | |||
| Debt/EBITDA | 1.35 | 1.95 | 0.55 | -0.46 | -0.65 | -2.32 | ||||
| R&D/CAPEX, % | 763.8% | 2 028% | 1 391% | 1 823% | 1 851% | 1 463% | ||||
| CAPEX/Revenue, % | 170.7% | 11.6% | 628.2% | 367.2% | 30.7% | 13.8% | ||||
| Bluebird Bio shareholders | ||||||||||
